Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Current Leases (2018 - 2026)

Cytosorbents filings provide 8 years of Current Leases readings, the most recent being $541000.0 for Q4 2025.

  • On a quarterly basis, Current Leases rose 19.43% to $541000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $541000.0, a 19.43% increase, with the full-year FY2025 number at $541000.0, up 19.43% from a year prior.
  • Current Leases hit $541000.0 in Q4 2025 for Cytosorbents, up from $518000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $570566.0 in Q4 2021 to a low of $108939.0 in Q4 2022.
  • Median Current Leases over the past 5 years was $414464.0 (2022), compared with a mean of $368718.6.
  • Biggest five-year swings in Current Leases: tumbled 80.91% in 2022 and later skyrocketed 268.59% in 2024.
  • Cytosorbents' Current Leases stood at $570566.0 in 2021, then tumbled by 80.91% to $108939.0 in 2022, then skyrocketed by 242.98% to $373636.0 in 2023, then rose by 21.24% to $453000.0 in 2024, then grew by 19.43% to $541000.0 in 2025.
  • The last three reported values for Current Leases were $541000.0 (Q4 2025), $518000.0 (Q3 2025), and $495000.0 (Q2 2025) per Business Quant data.